Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease.
about
Study of gene function based on spatial co-expression in a high-resolution mouse brain atlas6-[18F]fluoro-L-DOPA: a well-established neurotracer with expanding application spectrum and strongly improved radiosynthesesManganism in the 21st century: the Hanninen lecturePathophysiology of manganese-associated neurotoxicityA systematic review of biomarkers for disease progression in Alzheimer's diseaseTranslating principles of neural plasticity into research on speech motor control recovery and rehabilitation.A systematic review of biomarkers for disease progression in Parkinson's diseaseNeuroimaging of structural pathology and connectomics in traumatic brain injury: Toward personalized outcome prediction.Mapping the target localization and biodistribution of non-radiolabeled VMAT2 ligands in rat brain.The test-retest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function.Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseasesPersistent dopamine functions of neurons derived from embryonic stem cells in a rodent model of Parkinson diseaseBlood oxygenation level-dependent activation in basal ganglia nuclei relates to specific symptoms in de novo Parkinson's diseaseThe role of molecular imaging in the diagnosis and management of neuropsychiatric disorders.The nature of progression in Parkinson's disease: an application of non-linear, multivariate, longitudinal random effects modelling.Distribution of vesicular monoamine transporter 2 protein in human brain: implications for brain imaging studies.Changes in network activity with the progression of Parkinson's disease.Recent advances in imaging of dopaminergic neurons for evaluation of neuropsychiatric disorders.Positron emission tomography and single-photon emission computed tomography in central nervous system drug development.Low nigrostriatal reserve for motor parkinsonism in nonhuman primates.COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global--clinical evaluations, serum biomarkers, genetic studies and neuroimaging--prospective, multicenter, non-interventional, long-term study on Parkinson's disease progDoes dopamine dysfunction drive depression?Validation of nigrostriatal positron emission tomography measures: critical limits.Application of modified regression techniques to a quantitative assessment for the motor signs of Parkinson's disease.Protection against Parkinson's disease progression: clinical experience.Single photon-emission computed tomography imaging in early Parkinson's disease.Effects of the organochlorine pesticide methoxychlor on dopamine metabolites and transporters in the mouse brain.Multiple protonation states of vesicular acetylcholine transporter detected by binding of [3H]vesamicol.Imaging dopamine transporters in Parkinson's disease.Cerebrospinal fluid biomarker candidates for parkinsonian disorders.Neuroimaging biomarkers for Parkinson disease: facts and fantasy.Imaging synucleinopathies.Tau/α-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study.Decrease of nicotinic receptors in the nigrostriatal system in Parkinson's disease.Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease.PET Imaging of Serotonin Transporters With 4-[(18)F]-ADAM in a Parkinsonian Rat Model With Porcine Neural Xenografts.Noninvasive brain imaging for experimental medicine in drug discovery.Design, synthesis, and in vitro evaluation of quinolinyl analogues for α-synuclein aggregation.
P2860
Q21202800-DDA59E60-3597-432F-9CC7-38EC882E6056Q26991479-30C74435-2754-42E3-9CAA-4953A2387F9CQ27015750-12FF70F3-5F1A-4B0D-9AFF-7169936F388AQ28384357-EF501518-BBC5-4894-969B-072EDE844241Q28539868-4759D96A-4F62-4523-9C33-BC9100EB41D4Q28754738-4477A438-3C2C-4D43-B526-471CFAAB78CFQ30455202-32978F7F-6029-4175-BF52-BEE2BEEFE994Q30687519-09533174-12B0-42F9-B010-9237F64BB4EBQ33574108-59D96A60-9ADF-4C2E-A840-3040475A03BDQ33897463-07035917-C780-4892-BCC1-B6E297834C09Q34071942-B03F9910-81AD-4F5A-81D3-EEDBE3B8CE15Q34118080-37AA7F8B-99CE-4E69-9AE5-9625A608C1D1Q34185526-D238C773-1158-40CE-BFDC-1377DA34C167Q34897526-3E8430BC-EB01-4D18-9743-CBF6635E0B63Q35034718-A47B011B-280E-41A4-82C7-B10C876EB09BQ35524103-AA10B90C-C1A3-48F2-B066-D38E3E079455Q35679748-26EC76EE-37F0-4C11-B9E4-156FA24E98CBQ35910290-89005FCA-217F-4BEB-9356-C93475419514Q36129732-5C31DE38-076C-4558-9017-39EB31A810A3Q36236735-DFFE059F-4E7B-43C1-ACF4-72D91B410288Q36616565-D8DEBF1F-E9C4-49AE-8598-E2E8D1AB06C5Q36728907-38C7585A-B6C0-463C-8D3C-9E22FCD5AE64Q36780857-B080239A-EE7E-43F2-B257-3775194D93E6Q36971704-DB9E872B-1AF0-4756-BABD-0BE6E958DA7AQ37131239-BA4DA3B8-675F-4C6F-8206-DEB921281507Q37352055-30D20A8D-E2A2-4C9E-90D2-D4C7ABC3B575Q37401337-9D8ADB0D-D182-4B02-80F8-7C3D4B8AC3C4Q37474646-CC0E48E1-A22E-4EE9-8837-74509F14EBC0Q37800096-B38C9A01-DEFB-4F72-9745-D19FDBEF6CCBQ38076411-32A5778F-D205-45EF-8E81-0FCD4D3E2F27Q38264397-F97FBFC8-61BA-46FF-A755-8B095873A618Q38734660-5CDD40FE-E233-4296-8180-EA90D09FCF3EQ38761739-2F661489-662A-480D-AB44-45FA7C855929Q45985006-29C56F17-2EB1-4AE2-A6BC-F965034FA83AQ46900351-5824FDFE-6638-461A-92C7-C2F3804575D1Q48167667-7608C473-1A10-43AC-B882-B4496AA7A535Q48483635-40D01900-5FF4-497F-8EB3-EB89F08E1B50Q52684572-981A86A5-2195-4620-81DB-01518382B648
P2860
Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Assessment of neuroimaging tec ...... ession of Parkinson's disease.
@ast
Assessment of neuroimaging tec ...... ession of Parkinson's disease.
@en
type
label
Assessment of neuroimaging tec ...... ession of Parkinson's disease.
@ast
Assessment of neuroimaging tec ...... ession of Parkinson's disease.
@en
prefLabel
Assessment of neuroimaging tec ...... ession of Parkinson's disease.
@ast
Assessment of neuroimaging tec ...... ession of Parkinson's disease.
@en
P2093
P921
P1476
Assessment of neuroimaging tec ...... ession of Parkinson's disease.
@en
P2093
Prentice R
Stoessl AJ
P304
P356
10.1016/J.EXPNEUROL.2003.08.008
P407
P478
184 Suppl 1
P577
2003-11-01T00:00:00Z